EPO and COVID-19: <h4>Objectives</h4>To evaluate the effect of recombinant erythropoietin on hospitalised COVID-19 patients.<h4>Trial design</h4>Concealed, randomized, single-blinded, phase 2 controlled clinical trial with two arm parallel-group design of 20 patients allocated with 1:1 ratio and using the placebo in the control group.<h4>Participants</h4>This study will be performed at Shahid Mohammadi Hospital in Bandar Abbas, Hormozgan in Iran.